Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

17:37
 
Share
 

Manage episode 438151199 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.
Our Guest:
Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com
This episode was funded by Eli Lilly, Canada.

  continue reading

70 episodes

Artwork
iconShare
 
Manage episode 438151199 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.
Our Guest:
Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com
This episode was funded by Eli Lilly, Canada.

  continue reading

70 episodes

Alla avsnitt

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play